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Abstract  
Objective: The language currently used to describe gout lacks standardisation.  The aim of this 
project was to develop a consensus statement on the labels and definitions used to describe the 
basic disease elements of gout. 
 
Methods: Experts in gout (n=130) were invited to participate in a Delphi exercise and face-to-face 
consensus meeting to reach consensus on the labelling and definitions for the basic disease 
elements of gout.  Disease elements and labels in current use were derived from a content analysis 
of the contemporary medical literature, and the results of this analysis were used for item selection 
in the Delphi exercise and face-to-face consensus meeting.   
 
Results: There were 51 respondents to the Delphi exercise and 30 attendees at the face-to-face 
meeting.  Consensus agreement (≥80%) was achieved for the labels of eight disease elements 
through the Delphi exercise; the remaining three labels reached consensus agreement through the 
face-to-face consensus meeting.  The agreed labels were: monosodium urate crystals, urate, 
hyperuric(a)emia, tophus, subcutaneous tophus, gout flare, intercritical gout, chronic gouty arthritis, 
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imaging evidence of monosodium urate crystal deposition, gouty bone erosion and podagra.  The 
face-to-face meeting achieved consensus agreement for the definitions of all 11 elements and a 
recommendation that the label ‘chronic gout’ should not be used. 
 
Conclusion: Consensus agreement was achieved for the labels and definitions of 11 elements 
representing the fundamental components of gout aetiology, pathophysiology and clinical 
presentation.  The Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) 
recommends the use of these labels when describing the basic disease elements of gout. 
 
Significance and Innovations 
 The terminology currently used for gout lacks standardisation and has notable deficiencies in 
its precision, accuracy and clarity. 
 This international collaborative project provides a consensus statement on the labels and 
definitions given to the basic disease elements of gout. 
 It is hoped that the adoption this standardised nomenclature will benefit communications in 
gout-related research and management. 
 
The language used to describe gout has substantial deficiencies in both accuracy and precision 
[1,2,3].  A recent computational analysis of the medical literature found that the terminology used 
for gout, its treatment and outcomes, was inconsistent, ambiguous and frequently misleading [1].  A 
widely accepted nomenclature for gout would have important implications for standardisation in 
research and clinical settings. 
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The Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) is an international, 
multidisciplinary collaboration, dedicated to advancing the crystal deposition-associated disorders.  
In recognition of the current deficits in gout terminology, G-CAN has supported the development of 
a Gout Nomenclature Project, aimed at establishing consensus on the labels and definitions used to 
describe this disease.  The intended audience for this consensus statement includes health care 
professionals and non-physician scientists in both clinical and research settings.  Herein, we describe 
the methodology and results of the G-CAN Gout Nomenclature Project concerning the fundamental 
components of gout aetiology, pathophysiology and clinical presentation – referred to hereafter as 
the ‘basic disease elements’. 
 
MATERIALS AND METHODS 
There were three stages to this project.  A content analysis of the literature was undertaken to 
identify the basic disease elements and the labels currently used to denote them.  The findings from 
this analysis provided a framework for the subsequent group consensus exercises.  A Delphi exercise 
was utilized to achieve consensus agreement on the recommended labels for each disease element.  
A subsequent face-to-face consensus meeting had two aims: to reach agreement on any labels that 
had not achieved consensus through the Delphi exercise; and to reach consensus agreement on 
definitions for each of the disease elements.  An overview of the project is depicted in Figure 1. 
 
Content analysis of the literature 
The purpose of this analysis of the literature was to identify the range of elements that collectively 
represent the basic disease elements of gout.  Furthermore, it aimed to determine the number and 
frequency of labels used for each of these elements in the contemporary medical literature.  This 
analysis has been described separately [2].  Briefly, all journal articles containing reference to gout or 
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hyperuricaemia were examined within the ten highest ranked general rheumatology and five highest 
ranked general internal medicine journals (according to the 2015 Thomson-Reuters Journal Citation 
Reports) from 1st January 2012 to the 31st January 2017, inclusive. 
 
Delphi exercise 
The principles of the Delphi technique have been described in detail elsewhere [4].  In essence, it 
entails a series of rounds over which proposed options are sequentially refined by expert opinion 
until consensus is met.  The Delphi exercise in this project consisted of three rounds, each conducted 
as an online survey using QualtricsTM software (Qualtrics, Provo, Utah).  Experts in gout, identified by 
their membership of G-CAN, were invited by email to participate in the first survey (n=130).  
Members were invited to participate in subsequent rounds if they had completed the preceding 
survey. 
 
In each survey, the disease elements were represented using a variety of methods - descriptive text, 
clinical photographs, diagnostic images and graphs - to accurately portray the element in question.  
Respondents were asked to select and rank their preferred labels for each element.  The label 
options provided were derived from the content analysis of the literature and represented the most 
commonly identified labels.  Labels were not included if they had been identified less than twice in 
the body of literature examined and no more than ten options were given for each element.  There 
were two exceptions to this format.  The label ‘podagra’ was unique in that there were essentially no 
other labels identified through the literature analysis that referred to involvement of a specific 
anatomical region.  For this element, respondents were asked to vote whether ‘podagra’ was an 
acceptable label to denote ‘an episode of acute inflammation of the first metatarsophalangeal joint’ 
(with relevant images shown).  As ‘hyperuric(a)emia’ was the only label used to describe ‘an 
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elevated circulating level of the final enzymatic product generated by xanthine oxidase in purine 
metabolism’, respondents were asked to vote on whether this was an acceptable label for this 
element.  The label options provided in the first Delphi survey are shown in Supplementary Table S1. 
 
Respondents could comment on labels they felt strongly for or against.  In accordance with the 
principles of the Delphi process, the second and third rounds included group feedback consisting of 
previous results and thematic summaries of comments provided.  The label options in the second 
and third rounds were progressively refined depending on the achievement of consensus or other 
selection criteria.  Consensus was defined as at least 80% of respondents selecting a label as their 
first choice.  If consensus agreement had not been achieved for a label following the first round, it 
would be included as an option in the second-round if ranked within the top three by at least 20% of 
respondents.  The two top ranked labels from the second round were included in the third round in 
cases where consensus had not yet been reached. 
 
Face-to-face consensus meeting 
The face-to-face meeting was held on June 14th, before the EULAR 2017 Congress, Madrid, Spain.  
Invitations to attend were extended to all G-CAN members.  Participation in the Delphi process was 
not a pre-requisite for attendance.  The meeting was conducted as a facilitated discussion on a list of 
specific questions.  First, the group discussed and voted on labels for elements that had not achieved 
consensus through the Delphi process.  All attendees were given the opportunity to express their 
opinion on the remaining label options; however, the introduction of new labels was not permitted.  
Voting rounds, conducted by ‘show of hands’, were held for each of these labels.  Consensus was 
defined as at least 80% of participants in agreement for a proposed label.  Attendees who abstained 
from voting were not included in calculating the percentage of those in agreement. 
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After consensus had been achieved for all labels, the definitions for each element were addressed 
using the same facilitated discussion approach.  Prior to the meeting, draft definitions were 
circulated to attendees to provide a basis for these discussions.  Attendees could express their views 
on each element with the aim of constructing an accurate, yet concise, definition for each label.  Key 
concepts raised were documented and incorporated into sequentially modified definitions that were 
then put to a ‘show of hands’ vote.  This process continued until consensus agreement was 
achieved, defined as at least 80% agreeing with the proposed definition. 
 
G-CAN endorsement 
The results of the group consensus exercises and recommendations were submitted to the G-CAN 
Board of Directors, with endorsement following their review. 
 
RESULTS 
Content analysis of the literature 
Eleven basic disease elements of gout were identified; the text descriptions of these elements are 
shown in Table 1.  Further details on the range and frequency of labels used to describe these 
elements have been described in detail elsewhere [2]. 
 
Delphi exercise 
There were 51 G-CAN members who responded to the first survey (39% of all members).  The 
respondents included 19 members from Europe (37%), 16 from North America (31%), 11 from the 
Asia-Pacific region (22%), and five from Latin America (10%).  Respondents were predominantly 
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rheumatologists (n=46, 90%).  Of the respondents who completed the first survey, 48 (94%) 
completed all three rounds. 
 
At the completion of the Delphi exercise, consensus had been achieved for labels to describe eight 
of the eleven basic disease elements: monosodium urate crystals, urate, hyperuric(a)emia, 
intercritical gout, tophus, subcutaneous tophus, imaging evidence of monosodium urate crystal 
deposition, and podagra (Table 2). 
 
Consensus was not achieved through the Delphi process for the labelling of three elements.  The 
element described as ‘an episode of acute inflammation triggered by the presence of pathogenic 
crystals’, narrowly failed to achieve consensus; 79% of respondents preferred the label ‘gout flare’.  
For the element described as ‘persistent inflammation induced by pathogenic crystals’, preferences 
were divided between two labels; ‘chronic gout’ (69%) and ‘chronic gouty arthritis’ (23%).  
Consensus was also not achieved for the element described as ‘the presence of structural bone 
damage due to gout’; 65% preferred the label ‘bone erosion’, while 33% favoured ‘gouty erosion’. 
 
Face-to-face meeting 
The face-to-face consensus meeting was attended by 30 G-CAN members (23% of all members).  
Twenty-four (80%) of these attendees had also participated in the Delphi exercise.  The panel 
included 17 members from Europe (57%), six from the Asia-Pacific region (20%), five from North 
America (17%) and two from Latin America (7%).  Most attendees were rheumatologists (n=28, 
93%).  Some voting activities included only 29 attendees due to the late arrival of one member. 
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Disease element labels 
The face-to-face meeting was successful in achieving consensus agreement on the labelling of the 
three unresolved elements following the Delphi exercise.  These consensus element labels were: 
gout flare, chronic gouty arthritis and gouty bone erosion (Table 2).   
 
Consensus for the label ‘gout flare’ was achieved without additional discussion, with 26 of 29 
attendees (90%) voting in favour.  Group discussion identified that the text description ‘persistent 
inflammation induced by pathogenic crystals’ used in the Delphi exercise was ambiguous; this was 
thought to contribute to the failure to achieve consensus on the labelling of this element.  Although 
gout-related chronic inflammation has multi-system effects, this disease element was intended to 
represent persistent inflammation in joint structures.  Following this clarification, 24 of 29 (83%) 
voted in favour of ‘chronic gouty arthritis’ as the preferred label.  Furthermore, it was proposed that 
the label ‘chronic gout’ should be not be used.  The use of the word ‘chronic’ in this context was felt 
to be redundant and potentially confusing when gout, by its very nature, is characterised by chronic 
crystal deposition.  Consensus for the recommendation that “the label ‘chronic gout’ should be 
avoided” was achieved with 28 out of 29 (97%) voting in favour of this recommendation. 
 
When discussing the label for the element described as ‘the presence of structural bone damage due 
to gout’, it was proposed that ‘bone erosion’ and ‘gouty erosion’ be combined to form ‘gouty bone 
erosion’.  The group considered that the use of ‘gouty’ was desirable for disease specificity, and to 
maintain consistency in this same approach used with other consensus labels.  Inclusion of ‘bone 
erosion’ was judged to be in alignment with the accepted nomenclature of bone damage caused by 
other rheumatologic diseases.  Consensus agreement for the label ‘gouty bone erosion’ was 
achieved with 27 of 29 (97%) voting in favour. 
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Disease element definitions 
Consensus agreement was achieved for the definitions of all 11 basic disease elements of gout 
(Table 3).  Further details on voting results are included in Supplementary Table S2.  Relevant issues 
arising from group discussions on the composition of these definitions are outlined here. 
 
For ‘hyperuric(a)emia’, it was considered beyond the scope of this nomenclature project to include a 
specific threshold of blood urate concentration in its definition.  Apart from the complexities 
involving urate solubility, and the multifactorial relationship between circulating urate levels and the 
clinical presentation of gout, it was argued that a specific concentration may inadvertently promote 
a potentially inappropriate treatment target.  Therefore, the final accepted definition was modified 
to read ‘an elevated blood urate concentration over the saturation threshold’. 
 
For ‘gout flare’, it was agreed that the definition should include the qualifying description ‘a clinically 
evident episode’ as it was deemed important to specify that such an episode was detectable either 
by history or physical examination.  When considering ‘intercritical gout’, it was agreed to include 
the words ‘gout’ and ‘crystal deposition’ within the definition to reinforce the concept of gout as a 
chronic disease of crystal deposition, even in the absence of clinically evident acute inflammation.  
For the element labelled ‘chronic gouty arthritis’, it was agreed the definition should refer 
specifically to ‘joint’ involvement to maintain consistency with the use of ‘arthritis’ within the label. 
 
The definition for ‘imaging evidence of monosodium urate crystal deposition’ was constructed to 
include the phrase ‘findings that are highly suggestive of monosodium urate crystals on an imaging 
test’ as crystal deposits are not always directly visualised, depending on the imaging modality used.  
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The definition of ‘gouty bone erosion’ was worded to reflect the aforementioned changes in the 
element label.  The definition explicitly refers to ‘a cortical break in bone’ and the gout-specific 
radiologic findings of an ‘overhanging edge with sclerotic margins’.  Even with these characteristic 
findings, aetiologic association is addressed as ‘suggestive of gout’ in recognition that causality 
cannot be proven. 
 
The group recognised that the consensus definition for ‘podagra’ differs from the literal translation 
of this word (Greek: pod ‘foot’, agra ‘seizure/trap’).  However, it was accepted by most participants 
that this term has evolved to refer specifically to the first metatarsophalangeal joint rather than the 
entire first toe, foot or including the first interphalangeal joint. 
 
DISCUSSION 
We present the agreed labels and definitions for the basic disease elements of gout endorsed by G-
CAN (Table 3).  Our own research, consistent with that of others, has demonstrated considerable 
shortfalls in the terminology used to represent gout in the scientific literature [1,2].  The use of 
inconsistent, inaccurate and misleading terms has the potential to obscure interpretation of 
research and clinical communication.  A clear and agreed terminology of the basic disease elements, 
which promotes an improved conceptual understanding of the disease and its pathogenesis, could 
also have a positive impact on patient care. The objective of this project was to address these 
deficits by developing a complete nomenclature for these basic elements, based on consensus 
expert opinion. 
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One of the important outcomes of this project is the agreement reached on the labelling of the 
element ‘urate’.  The common use of ‘uric acid’ for this element, often interchangeably with ‘urate’, 
is a potential source of confusion to clinicians, researchers and patients alike [2].  The label ‘urate’ is 
consistent with the biochemical characteristics of uric acid as a weak acid that is largely ionised at pH 
7.4, thereby making it the predominant form in blood [5]. 
 
This consensus statement also makes important recommendations on the nomenclature of 
elements that refer to the clinical features of gout.  A key consideration is the commonly used 
classification of gout as being either ‘acute’ or ‘chronic’.  The label ‘acute gout’ suggests that the 
deleterious effects of this disease are limited only to those periods of intense inflammatory response 
triggered by the presence of monosodium urate crystals.  In the medical literature, the label ‘chronic 
gout’ has been used by some authors to imply a distinct presentation of the disease; such as the 
presence of structural joint disease or extensive tophi [6,7].  These two commonly used labels 
misrepresent the pathophysiology of gout, an inherently chronic disease, in which crystal deposition 
is present regardless of the inflammatory state.  The labels recommended by G-CAN in this 
consensus statement reflect contemporary understanding of disease pathophysiology.  Adoption of 
this nomenclature may help overcome the common misperception of gout as an episodic disease 
which requires only acute management [8]. 
 
The label ‘tophus’ (Latin: ‘stone’) is inextricably linked to the clinical manifestations of monosodium 
urate (MSU) crystal deposition [9,10].  In this consensus statement, we recommend the label 
‘tophus’ when referring generally to MSU deposition and its host tissue response.  The label 
‘subcutaneous tophus’ should be used for tophi evident on physical examination; the use of 
‘subcutaneous’ is intended to add specificity while recognizing that tophi may in fact occur in other 
clinically-evident anatomical locations (e.g., intradermal).  When referring to crystal deposits 
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detectable by imaging, the label ‘imaging evidence of monosodium urate crystal deposition’ should 
be used.  The label and definition for this element are applicable to any form of imaging; modality-
specific nomenclature falls outside the scope of this project.  For ‘gouty bone erosion’, this label and 
its definition recognize the characteristic appearance of bone damage in gout. 
 
Finally, this consensus statement supports the use of ‘podagra’ to represent the element of a gout 
flare affecting the first metatarsophalangeal (MTP) joint.  This is a commonly used term that has 
been associated with gout for many centuries [9,10].  Due to its historical significance and 
widespread acceptance, the use of this label has been deemed acceptable. 
 
A limitation of this project is that it addresses only the basic disease elements of gout and not the 
name of the disease itself; nor does it deal with the nomenclature for disease staging, management 
and outcome measures.  However, establishing a nomenclature of the basic elements was 
prioritized due to the foundation it provides for the labelling of more complex concepts; these are 
intended to be addressed in future work by G-CAN.  The response rate to the group consensus 
exercises was modest, (39% for the Delphi, 23% for the face-to-face consensus meeting) and 
participants were predominantly male (73%).  There was, however, international representation 
from experts in the field.  A further potential limitation was the use of existing terminology identified 
by a content analysis of the medical literature, rather than devising novel terms.  This decision was 
made to avoid adding to the already vast array of terms used to describe gout [2].  Refinement of 
established terminology was considered the most effective way of expediting widespread 
acceptance amongst clinicians and non-physician researchers. 
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In summary, this G-CAN consensus statement regarding the labels and definitions for basic disease 
elements in gout represents an important step in promoting standardized nomenclature for the 
fundamental elements of this disease.  Consensus terminology for the basic disease elements is a 
fundamental requirement for further work to address more advanced concepts, including the 
disease states of gout.  The Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) 
recommends the use of these labels when describing the basic disease elements of gout in clinical 
settings and in the scientific literature, with the goal of improving the accuracy and consistency of 
the language used to describe gout. 
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Figure 1 – Schema for the Gout Nomenclature Project. 
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Table 1.  Text descriptions of the basic disease elements of gout identified in a content analysis of 
published literature. 
1. The pathogenic crystals in gout 
2. The circulating form of the final enzymatic product generated by xanthine oxidase in purine 
metabolism in humans 
3. An elevated circulating level of the final enzymatic product generated by xanthine oxidase in purine 
metabolism in humans 
4. An episode of acute inflammation triggered by the presence of pathogenic crystals 
5. The condition in which there is an absence of clinically evident inflammation after or between 
episodes of acute inflammation 
6. Persistent inflammation induced by pathogenic crystals 
7. A discrete collection of pathogenic crystals with associated host-response tissue 
8. A discrete collection of pathogenic crystals with associated host-response tissue, detectable on 
physical examination 
9. The presence of pathogenic crystal deposition on imaging 
10. The presence of structural bone damage due to gout 
11. An episode of acute inflammation of the 1st metatarsophalangeal joint 
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Table 2.  Results of a Delphi exercise and face-to-face consensus meeting for agreement on the 
labels for the basic disease elements of gout.  Consensus was defined as 80% or more agreement on 
the preferred label. 
 
Text description of element
 
Delphi exercise Face-to-face meeting 
Agreed label 
Consensus 
achieved 
(round) 
Agreement 
% 
Consensus 
achieved 
Agreement 
% 
1. The pathogenic crystals in 
gout 
Yes (1) 92% - - 
Monosodium 
urate crystals 
2. The circulating form of the 
final enzymatic product 
generated by xanthine oxidase 
in purine metabolism in 
humans 
Yes (3) 81% - - Urate 
3. An elevated circulating level 
of the final enzymatic product 
generated by xanthine oxidase 
in purine metabolism in 
humans 
Yes (1) 91% - - Hyperuric(a)emia 
4. An episode of acute 
inflammation triggered by the 
presence of pathogenic crystals 
No - Yes 83% Gout flare 
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5. The condition in which there 
is an absence of clinically 
evident inflammation after or 
between episodes of acute 
inflammation 
Yes (3) 81% - - Intercritical gout 
6. Persistent inflammation 
induced by pathogenic crystals 
– involving articular structures
*
 
No - Yes 83% 
Chronic gouty 
arthritis 
7. A discrete collection of 
pathogenic crystals with 
associated host-response tissue 
Yes (1) 88% - - Tophus 
8. A discrete collection of 
pathogenic crystals with 
associated host-response 
tissue, detectable on physical 
examination
 
Yes (3) 83% - - 
Subcutaneous 
tophus 
9. The presence of pathogenic 
crystal deposition on imaging 
Yes (2) 86% - - 
Imaging evidence 
of MSU crystal 
deposition 
10. The presence of structural 
bone damage due to gout 
No - Yes 97% 
Gouty bone 
erosion 
11. An episode of acute 
inflammation of the 1st 
metatarsophalangeal joint 
Yes (1) 84% - - Podagra 
*
Italics refers to modification of text description as presented in the face-to-face meeting 
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Table 3.  G-CAN endorsed labels and definitions of the basic disease elements of gout following a 
Delphi exercise and face-to-face consensus meeting. 
 
 
Consensus label Consensus definition 
1. Monosodium urate crystals 
The pathogenic crystals in gout (chemical formula: 
C5H4N4NaO3). 
2. Urate 
The circulating form of the final enzymatic product generated 
by xanthine oxidase in purine metabolism in humans (chemical 
formula: C5H3N4O3
-
). 
3. Hyperuric(a)emia 
Elevated blood urate concentration over the saturation 
threshold. 
4. Gout flare 
A clinically evident episode of acute inflammation induced by 
monosodium urate crystals. 
5. Intercritical gout 
The asymptomatic period after or between gout flares, despite 
the persistence of monosodium urate crystals. 
6. Chronic gouty arthritis 
Persistent joint inflammation induced by monosodium urate 
crystals. 
6a. G-CAN recommendation The label ‘chronic gout’ should be avoided. 
7. Tophus 
An ordered structure of monosodium urate crystals and the 
associated host tissue response. 
8. Subcutaneous tophus 
A tophus that is detectable by physical examination. 
9. Imaging evidence of monosodium 
urate crystal deposition 
Findings that are highly suggestive of monosodium urate 
crystals on an imaging test. 
10. Gouty bone erosion 
Evidence of a cortical break in bone suggestive of gout 
(overhanging edge with sclerotic margin). 
11. Podagra A gout flare at the 1
st
 metatarsophalangeal joint. 
